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ABSTRACT
Aim: To investigate the effect of timolol and latanoprost
on the extracellular matrix organisation, inflammatory
infiltration, and expression of matrix metalloproteinases
(MMPs) and tissue inhibitors of matrix metalloproteinases
(TIMPs) in the human conjunctiva.
Methods: Conjunctival biopsies were obtained from the
inferior fornix during routine cataract surgery from 20
patients with primary open-angle glaucoma, who had
received a monotherapy either with timolol or latanoprost,
and from 10 non-glaucomatous patients. Specimens were
investigated by light microscopy, immunohistochemistry
using antibodies against MMP-1,-3, TIMP-2,-3 and CD 68
antibodies and by quantitative transmission electron
microscopy.
Results: The number of collagen fibres was significantly
decreased in latanoprost-treated conjunctival specimens
compared with timolol-treated eyes (p,0.01) but
showed no difference to controls. Amorphous material
was increased in both treated groups compared with
controls (p,0.001) but was less in latanoprost-treated
specimens compared with timolol-treated eyes
(p,0.001). Optically clear spaces, probably containing
glycosaminoglycans, were significantly reduced in both
treated groups—with less of a reduction in latanoprost—
compared with timolol-treated eyes (p,0.001). A marked
upregulation of MMP-1 and MMP-3 and moderately
increased staining for TIMP-2 and TIMP-3 was found in
epithelial cells and subepithelial stromal cells of latano-
prost-treated eyes. A moderate infiltration with macro-
phages and inflammatory cells was observed in timolol-
treated eyes.
Conclusions: Latanoprost-treated conjunctival speci-
mens showed a decreased stromal collagen density and a
less pronounced inflammatory infiltration. The upregula-
tion of MMP-1 and MMP-3 in latanoprost-treated eyes
might explain the reduced extracellular matrix accumula-
tion in the conjunctival stroma. Therefore, latanoprost
therapy might have a more favourable effect on the
outcome of glaucoma filtering surgery.
Antiglaucoma drug medication is the major treat-
ment modality for glaucoma. There is increasing
evidence that the long-term use of topically adminis-
tered medication affects the structure and integrity
o ft h ec o n j u n c t i v a lt i s s u ea n dt h eo c u l a rs u r f a c e .
1–8
On the other hand glaucoma filtering surgery
frequently fails mostly due to fibrosis at the
episcleral-, conjunctival/Tenon capsule interface.
9
Several studies have already suspected a link
between an altered histomorphology of conjuncti-
val tissue due to long-term antiglaucoma medica-
tion and the risk of filtering failure in patients who
had undergone trabeculectomy.
10 Sherwood et al
suggested that chronic topical antiglaucoma med-
ication increased the likelihood of fibrosis and
subsequent bleb failure.
11
A previous study investigating the long-term
effect of two commonly used antiglaucoma med-
ications, latanoprost and timolol, on the rabbit
conjunctiva demonstrated significant differences
regarding extracellular matrix composition in the
conjunctival stroma between both medications.
12
Additionally, an upregulation of specific matrix
metalloproteinases in the latanoprost treated speci-
mens was detected.
In the present study, we investigated the long-
termeffectof both antiglaucoma medications on the
human conjunctiva. In particular, we analysed the
extracellular matrix organisation, inflammatory
infiltration and expression of matrix metalloprotei-
nases (MMPs) and their inhibitors (TIMPs) using
immunhistochemistry and electron microscopy.
MATERIAL AND METHODS
Patients
Based on a statistical power calculation estimating
the number of collagen fibres, the amount of
amorphous material and empty spaces in the 30
subepithelial layer participants were included in
this study. For this estimation, a=0.05 and
b=0.20 (power of 80%). According to the equa-
tion n=7.856(SD/difference of the means)
2, the
required number of participants for the parameter
collagen fibres (SD 4.4 AU, difference of the means
4.0 AU) was n=10, for the parameter amorphous
material (SD 3.9 AU, difference of the means
4.8 AU) n=6 and for the parameter empty spaces
(SD=6.3 AU, difference of the means 17.0 AU)
n=3. The study protocol was approved by the
ethics committee of Dresden following the declara-
tion of Helsinki. All subjects were recruited from
the Department of Ophthalmology (University of
Dresden). All subjects signed an informed consent
before participating in this trial. Patients were
divided into three groups according to the type of
topical therapy administered (table 1).
The inclusion criteria for this study were as
follows: patients with primary-open angle glau-
coma or ocular hypertension treated with a
monotherapy of timolol 0.5% (n=10, mean age
75 (7) years) (Tim-ophthal 5 mg/ml, Novartis) or
0.005% latanoprost (n=10, mean age 74
(10) years), (Xalatan 50 mg/ml, Pharmacia,
Karlsruhe, Germany) for a period of at least
15 months and normal subjects without glaucoma
receiving no topical medication (n=10, mean age
76 (6) years). Intraocular pressure (IOP) measure-
ments in normal subjects were 22 mm Hg or less,
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normal if they had intact rims, no haemorrhages, notches,
excavation, nerve fibre defects, or asymmetry of the vertical C/
D ratio more than 0.2. In ocular hypertensive patients, IOP
measurements were 23 mm Hg or greater on at least two
occasions. Inclusion criteria for the optic disc were the same as
in the normal group. Patients with primary open-angle
glaucoma were included only if their optic discs were
glaucomatous based on neuroretinal rim thinning, notching,
excavation, nerve fibre layer defect or asymmetry of the vertical
C/D ratio more than 0.2 between both eyes. Visual field and
IOP were not used to define glaucoma.
Exclusion criteria were: inflammatory diseases of the eye, the
intake of medication affecting wound healing (e. g steroids or
immunosuppressors), participants younger than 18 years, scar-
ring diseases of the mucosa and other disorders of wound
healing.
After informed consent, 262 mm conjunctival biopsies from
the inferior fornix of the conjunctiva were obtained during
routine cataract surgery from the 20 glaucoma patients and
from the 10 non-glaucomatous subjects. The specimens were
bisected, immediately immersed in the appropriate fixative and
transferred to the Department of Ophthalmology, University of
Erlangen-Nuernberg, for morphological and immunohistochem-
ical analysis.
Methods
Immunohistochemistry
The first halves of the specimens were fixed in 4% parafor-
maldhyde in PBS and embedded in paraffin according to
standard protocols. Light-microscopic immunohistochemistry
was performed on 5 mm thick paraffin sections using the
peroxidase labelled streptavidin-biotin method (LSAB Plus kit;
Dako, Glostrup, Denmark) according to the manufacturer’s
instructions. Briefly, sections were incubated for 30 min each
with monoclonal mouse anti-rabbit MMP-3 (stromelysin),
monoclonal mouse anti-rabbit MMP-1, mouse anti-TIMP-2,
anti-TIMP-3 and anti-CD 68 antibodies (Chemicon, Temecula,
California) at a concentration of 5 mg/ml, with the biotinylated
link antibody and horseradish peroxidase (HRP)-conjugated
streptavidin. Proteolytic predigestion using proteinase K was
performed for 6 min. 3-Amino 9-ethyl carbazole was used as a
chromogenic substrate and Mayer haemalum as a counterstain.
In negative control experiments, the primary antibody was
omitted or replaced by equimolar concentrations of preimmune
mouse immunoglobulin G.
Transmission electron microscopy
The second halves of the specimens were fixed in 2%
glutaraldehyde in PBS and further processed by postfixation in
2% buffered osmium tetroxide and embedded in epoxy resin
(Epon 812; Fluka, Buchs, Switzerland) according to standard
protocols.
Semithin sections were stained with Toluidine Blue, and
ultrathin sections were stained with uranyl acetate and lead
citrate and examined with a transmission electron microscope
(EM 906E; Leo, Oberkochen, Germany).
For quantitative analysis of extracellular parameters (collagen
fibres, amorphous substance, electron-lucent spaces), an auto-
mated image-processing system (DigiVision; Leo) with an
integrated software package (Analysis; Soft Imaging Systems,
Muenster, Germany) was used. Measurements were performed
according to a defined random sampling procedure, using the
bars of the supporting grid square as points of reference, by
which 10 consecutive areas adjacent to the right side of a grid
bar were analysed. Ten measurements per specimen were
performed in the subepithelial stroma and 10 in the deeper
stroma at a distance of approximately 100 mm from the
epithelial basement membrane. Only areas including extracel-
lular matrix but avoiding areas with cells or blood vessels were
examined. The size of the area analysed was 66.8 mm
2 at a
magnification of 40006. The different grey values of the
structural parameters measured (collagen fibres, amorphous
material, empty spaces) were transformed into false colours
(red, green and white), and the percentage areas occupied by the
different colour-coded phases were automatically calculated.
For statistical analysis of the automatically measured areas,
the mean (SD) of the individual 10 measurements was
calculated for each layer and tissue component. These mean
values were then compared between the control and the treated
groups regarding each different component. For this purpose,
the non-parametric Mann–Whitney test was used. A p value of
,0.05 was considered statistically significant.
RESULTS
Light microscopy
In the control group, the conjunctiva consisted of a normal
goblet-cell-containing epithelium with an intact epithelial
basement membrane, loose collagenous connective tissue, and
no acute or chronic inflammation in the substantia propria. In
semithin sections, an increase in the density of the collagen
fibres in the substantia propria was present in eyes treated with
timolol but not in eyes treated with latanoprost.
Immunohistochemistry
MMPs
In the control group no staining with either the MMP-1 or
MMP-3 antibodies was observed, either in the epithelium or in
the stroma of the conjunctival specimens (fig 1C,F). In
latanoprost-treated conjunctival tissue, a marked upregulation
of MMP-1 and MMP-3 was found in the epithelial cells as well
as in the subepithelial stroma cells but not in the extracellular
matrix (fig 1A). In the timolol-treated specimens, immunoreac-
tions were less pronounced, revealing a very weak positive
reaction of staining in the epithelium and the stroma (fig 1B,E).
Table 1 Clinical data
Group
No of
subjects (n)
Mean age
(years)
Concentration
(mg/ml)
Applications
per day Preservative
Concentration
(mg/ml) of
benzalkonium
chloride
Control 10 76 (6) – – – –
Timolol 10 75 (7) 5.0 Twice BAC 0.1
Latanoprost 10 74 (10) 0.05 Once BAC 0.2
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Staining with antibodies to TIMP-1 and TIMP-3 was negative
in the control group (fig 1I,L). The latanoprost-treated speci-
mens showed moderately increased staining for TIMP-2 and
TIMP-3 in the epithelial cells as well as in subepithelial stroma
cells. The timolol-treated eyes revealed a very weak staining
with TIMP-1 or TIMP-2 in the epithelium. Similar to the MMP-
1 and MMP-3 pattern, TIMPs were immunolocalised to cells but
not to the extracellular matrix.
CD-68
A moderate infiltration with CD-68-positive macrophages was
observed in timolol-treated specimens only (fig 2A), whereas no
inflammatory reaction was observed in the latanoprost treated
group (fig 2B) or in the control group (not shown).
Quantitative electron microscopy
According to the different intensity of grey values, the three
extracellular components collagen fibres, amorphous material
and optically clear spaces were coded by false colours red, green
and white (fig 3). The area occupied by each colour was
automatically measured, and the percentage of each area in
relation to the whole field was calculated (table 2).
Conjunctival specimens of the control and latanoprost group
revealed a loose arrangement of extracellular matrix compo-
nents with a moderate collagen density and enlarged empty
spaces. Amorphous material was only focally present in
latanoprost treated eyes (fig 3A,B,D,E).
In contrast, in the timolol group collagen fibres appeared
augmented in the deep stroma relative to latanoprost, amor-
phous material in both the subepithelial and deeper stromal
layers relative to the latanoprost and control group (fig 3,C,F).
Collagen fibres
In the deeper stroma, the mean percentage of area occupied by
collagen fibres was significantly decreased in latanoprost-treated
specimens (31.8%) as compared with timolol-treated eyes
(36.6%) (p,0.01, fig 4). The mean percentage area in the
control group was 33.5%, which showed no significant
difference compared with the other groups (p.0.05). In the
subepithelial layer, no significant difference in the area occupied
by collagen could be observed between the three groups
(p.0.05, table 2).
Amorphous material
In both the subepithelial and deeper stroma, the amount of
amorphous material was increased in both treated groups as
Table 2 Analysis of extracellular conjunctival tissue changes: area occupied by collagen fibres, amorphous
material and empty spaces in the subepithelial and deep layer in the control-, timolol- and latanoprost group
Group Collagen fibres Amorphous material Empty spaces
Subepithelial layer
Control 40.3 (15.3) 30.9 (12.8) 28.8 (20.2)
Timolol 43.3 (17.4) (p.0.05) 43.3 (13.2) (p,0.001) 13.4 (9.5) (p,0.001)
Latanoprost 42.9 (13.2) (p.0.05) 38.1 (10.1) (p,0.001) 19.0 (10.5) (p,0.01)
Deep layer
Control 33.5 (14.6) 26.6 (12.2) 39.9 (20.9)
Timolol 36.6 (13.2) (p.0.05) 35.1 (9.8) (p,0.001) 32.8 (15.1) (p,0.05)
Latanoprost 31.8 (10.4) (p.0.05) 31.1 (10.4) (p,0.001) 32.7 (14.9) (p,0.05)
Data are presented as mean percentage (SD) (p values) relative to control group are indicated below.
Figure 1 Immunohistochemical staining
of MMP-1 (A–C) and MMP-3 (D–F),
TIMP-2 (G–I) and TIMP-3 (J–L) in the
conjunctival specimens of control and
study groups.
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difference was less pronounced in latanoprost-treated specimens
(38% and 31%) as compared with timolol-treated eyes (43% and
35%) (fig 5, table 2).
Empty spaces
In both the subepithelial and deeper stroma, 30–40% of the area
measured appeared as optically clear spaces, probably contain-
ing glycosaminoglycans, in control eyes, with a significant
reduction in both medically treated groups. Subepithelially, the
percentage area of empty spaces was significantly higher in
latanoprost-treated specimens (19%) compared with timolol-
treated eyes (13%) (p,0.001, fig 6, table 2).
DISCUSSION
Several studies have already focused on the impact of long-term
topical antiglaucoma medication on the histopathology of the
conjunctiva and their possible effect on the outcome of filtering
surgery. These studies reported a decrease in epithelial goblet
cells,
2 an increase in subepithelial collagen
3 and increased
amounts of macrophages, lymphocytes and mast cells in the
substantia propria.
11 0Moreover, topical antiglaucoma medica-
tion led to a significant degree of squamous metaplasia of
conjunctival specimens
13 and caused damage to the ocular
surface.
14 15
The additional effect on these conjunctival changes by
preservatives applied with the therapeutic agent has already
been discussed in detail. BAC is the most commonly used
preservative in eye-drops. In our study, the final BAC
concentration applied within latanoprost and timolol was the
same in sum (0.2 mg/ml) so that the conjunctiva in both groups
was exposed to similar BAC effects. Interestingly, a recently
published study by Liang et al
16 showed that the new
preservative-free tafluprost in contrast to latanoprost and
BAC alone was less toxic in the rabbit conjunctica, indicating
a good tolerability probably linked to the absence of preservative
in the solution. In extrapolation, latanoprost induced less
toxicity on the rabbit ocular surface than BAC. Pisella et al
demonstrated in vitro and in vivo studies in which BAC-
containing latanoprost and timolol exerted higher proinflam-
matory and proapoptotic effects on conjunctival cells than
unpreserved substances.
17 Preserved latanoprost, however,
caused less toxicity than preserved timolol, and both drugs
were less toxic than BAC alone.
17 These results suggest a
potential protective effect of the prostaglandin analogue and, to
a lesser extent, of timolol against the toxicity of BAC in
conjunctival cells. Guenoun et al assumed a protective effect of
latanoprost against BAC toxicity probably being related to the
antioxidative properties of latanoprost.
18
In the present study the effect of latanoprost and timolol on
the extracellular matrix (ECM) organisation, expression of
matrix metalloproteinases (MMPs) and their inhibitors (TIMPs)
on the human conjunctiva was investigated. MMPs form a
group of proteolytic enzymes responsible for catalysing ECM
degradation. TIMPs are involved in the maintenance of the
ECM. The levels of MMPs, TIMPs and their isoforms have
already been found in the ciliary body,
19 aqueous humour,
20
conjunctiva
21 and optic-nerve head.
22
An investigation of the TIMP level in aqueous humour
detected an increase in TIMP-1 concentration in eyes with
POAG in contrast to control eyes.
23 Aqueous samples from these
patients were also shown to increase collagen synthesis in vitro.
According to these findings, the authors suspected that an
Figure 2 Immunolocalisation of CD 68 indicating macrophages in the
conjunctival tissue of eyes treated with timolol (A) and latanoprost (B).
Figure 3 Quantification analysis of
extracellular matrix components in the
conjunctival stroma: (A–C) electron
micrograph showing collagen fibres
(small arrow), amorphous material (large
arrow), and optically clear spaces
(arrowhead) in the control, timolol and
latanoprost group: (D–F), original
magnification 34 0006.
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degradation may contribute to excessive deposition of collagen
with loss of the trabecular cells during the development of
POAG. Correspondingly, Ocklind et al observed in latanoprost-
treated specimens of monkey eyes an increased expression of
MMP-2 and MMP-3 and a decrease in collagen type IV and VI in
the anterior part of the ciliary muscle
24 suspecting that
latanoprost-induced changes in the extracellular matrix might
augment the flow of aqueous humour through the ciliary
muscle bundles of the uveoscleral pathway. Additionally,
Weinreb et al detected secretion of MMP-1 and MMP-9 in
ciliary smooth muscle cells which was increased by application
of prostaglandins.
25
Increased levels of MMPs and TIMPs were also observed in
diseases with an enhanced synthesis of ECM, like fibrotic
disorders,
28–31 proposing that MMPs and TIMPs are essential for
the control of tissue remodelling after filtering surgery.
26 Of
note, MMPs and TIMPs were not found to be expressed in
normal conjunctiva.
27
In consistency with previously published data, in our study
MMP-3 and MMP-1 expression was noted in the latanoprost
treated conjunctival specimens but not in control eyes or
timolol-reated eyes. The upregulation of MMPs might be based
on the direct effect of prostaglandins. The increased expression
of MMP-3, MMP-1, TIMP-1 and TIMP-2 in the latanoprost
group may be related to the reduced collagen fibre density,
indicating a direct effect of MMPs in terms of degrading the
ECM. In contrast, in timolol-treated eyes, a very weak
expression of MMPs and TIMPs was detected, but both the
number of stromal and subepithelial collagen fibres and the
amount of amorphous material, probably consisting of proteo-
glycans, were increased. Taking into account the study results
of Mietz et al,
12 a similiar MMP/TIMP-expression pattern was
found in our study. Both the immunohistochemical staining
and the transmission electron microscopy revealed remarkably
similar results in the rabbit conjunctiva and the human
conjunctiva.
In latanoprost-treated eyes, the amount of collagen fibres and
amorphous material was lower, and the expression of MMPs
and TIMPs was upregulated compared with the timolol group.
As already reported, scarring and ECM accumulation within the
subconjunctival space may be mainly responsible for filtering
failure after trabeculectomy, suggesting that the stimulation of
ECM degradation may suppress subconjunctival scar formation
and promote longer survival of filtering blebs.
32 Interestingly,
electron microscopy of failed filtering blebs revealed a dense
collagenous connective tissue as observed in our timolol-treated
eyes. In contrast, in functioning blebs the subepithelial
connective tissue was loosely arranged and contained histolo-
gically clear spaces,
33 which was consistent with histological
findings of our latanoprost-treated eyes. Of note, these clear
spaces corresponded in size and position to microcystic spaces
clinically.
33 The clinical use of latanoprost for treatment of
glaucoma might have two advantages. The main advantage of
latanoprost is the potent efficiacy in lowering IOP. A second
advantage might be the beneficial or less adverse effects that it
has on the conjunctiva with respect to potential wound-healing
processes following filtration surgery. Both factors seem to be
related to each other. In this context, immunohistochemical
data from Sagara et al revealed that intraocular pressure
reduction which occurred with topical prostaglandin F2alpha
Figure 4 Mean percentage (%) of collagen fibres in the subepithelial
and deep layer in the control group (white column), timolol group (grey
column) and latanoprost group (black column); *p,0.05, **p,0.01,
***p,0.001.
Figure 5 Mean percentage (%) of amorphous material in the
subepithelial and deep layer in the control (white column), timolol (grey
column) and latanoprost group (black column); *p,0.05, **p,0.01,
***p,0.001.
Figure 6 Mean percentage (%) of empty spaces in the subepithelial
and deep layer in the control-, (white column), timolol-, (grey column)
and latanoprost group (black column); *p,0.05, **p,0.01,
***p,0.001.
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uveoscleral outflow pathway in the anterior segment tissue of
monkey eyes.
34
In contrast, timolol-treated eyes showed an upregulation of
CD 68 antibodies, which is an indicator for acute and chronic
inflammatory infiltration. This observation suggests that long-
term timolol treatment might be associated with a potentially
higher risk for scarring processes around the scleral flap and a
less successful long-term outcome after filtering surgery due to
the altered histopathology.
In conclusion, our study data underlined that histomorpho-
logical changes were less pronounced in latanoprost-treated eyes
compared with timolol-treated subjects, even in the human
conjunctiva. The clinical relevance of the observed effects must
be investigated in everyday practical experience especially with
regard to the surgical outcome of filtering surgery after long-
term use of timolol and latanoprost.
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